EX-99.1 5 ex99-1.htm EX-99.1

 

Exhibit 99.1

 

 

 

LifeMD Reports Third Quarter 2026 Results

 

●Third quarter 2026 revenue of $44.6 million; adjusted EBITDA loss of approximately $0.4 million, within the Company’s guidance range of negative $1 million to positive $2 million.
●Adjusted EBITDA improved approximately $3.1 million sequentially from an adjusted EBITDA loss of $3.5 million in the second quarter of 2026, driven primarily by a 34% sequential reduction in selling and marketing expenses and reduction of overall non-clinical expenses.
●GAAP net loss from continuing operations attributable to common stockholders of $5.2 million, or $0.11 per share, compared with $8.4 million, or $0.18 per share, in the second quarter of 2026.
●Total active subscribers increased 13% year-over-year to approximately 350,000.
●LifeMD Pharmacy shipment volume grew 58.3% year-over-year.
●Exited the quarter with $21.9 million of cash and no debt; subsequent to quarter-end, closed on a $12.5 million senior secured term loan to replace the Company’s previous credit facility.
●Entered into arrangements with both Novo Nordisk and Eli Lilly, enabling LifeMD’s pharmacy to begin dispensing self-pay branded GLP-1 medications, including Wegovy, Wegovy Pill, Ozempic, Zepbound, and Foundayo, to patients nationwide.
●Entered into an exclusive relationship with AT&T to provide its 100 million wireless and fiber customers and 110,000 U.S. employees access to LifeMD’s healthcare and pharmacy services.
●Expecting fourth quarter 2026 revenue of between $46 million and $49 million, and Adjusted EBITDA of between negative $4 million to negative $2 million.

 

Conference call begins at 4:30 p.m. Eastern time today

 

NEW YORK, November 12, 2026 (GLOBE NEWSWIRE) — LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today reported financial results for the third quarter ended September 30, 2026.

 

Management Commentary

 

“We ended the quarter with approximately 350,000 active subscribers, up 13% from a year ago and nearly flat from the second quarter, despite spending $9.5 million less on marketing,” said Justin Schreiber, Chairman and CEO of LifeMD. “We’re helping more people access high-quality healthcare, and we’re getting more efficient at doing it. From May to September, cost per acquisition fell 32% while monthly media spend declined 45%. Adjusted EBITDA improved approximately $3.1 million sequentially to roughly breakeven, and we expect to sustain or improve these unit economics going forward.

 

“Revenue of $44.6 million was below our guidance, and we are resetting our outlook for the fourth quarter and full year. We deliberately reduced marketing spend and prioritized longer patient commitments, and our partnerships took longer to ramp than we expected. Those factors weighed on revenue this quarter, but we believe our decisions put us in a stronger position to grow profitably.

 

 

 

 

“Our pharmacy has begun dispensing branded GLP-1 medications from Eli Lilly and Novo Nordisk. Our exclusive relationship with AT&T gives its 100 million wireless and fiber customers and 110,000 U.S. employees access to our healthcare and pharmacy services. We also made significant progress on our enterprise healthcare offering, which we will begin marketing to businesses across the country in the fourth quarter. Our women’s health program continued to improve, and we added experienced leadership to accelerate its growth. Our focus now is turning this work into revenue growth while maintaining the operating discipline we established this quarter.”

 

“Gross margin was approximately 82% in the quarter, compared with approximately 89% in the second quarter and 85% a year ago. The decline primarily reflects a change in presentation, not economics: under our new branded fulfillment arrangements, medications fulfilled by our own pharmacy are recognized on a gross revenue basis,” said Atul Kavthekar, Chief Financial Officer of LifeMD. “We reduced selling and marketing expense by $9.5 million sequentially to $18.5 million. General and administrative expense increased slightly from the second quarter to $14.7 million, reflecting clinical capacity added to support our new partnerships, partially offset by efficiencies in non-clinical functions. We ended the quarter with $21.9 million of cash and no debt. Subsequent to quarter end, we closed a $12.5 million non-convertible senior secured term loan with Avenue Capital. It replaces our prior revolving credit facility and gives us significantly greater flexibility to fund the working capital our branded fulfillment arrangements may require.”

 

Third Quarter 2026 Financial Highlights

 

All comparisons are with the third quarter of 2025 on a continuing operations basis (excluding WorkSimpli, which was divested on November 4, 2025, and is reported as discontinued operations for all periods presented). Non-GAAP financial measures referenced below are defined and reconciled to the most directly comparable GAAP measures at the end of this press release.

 

●Total revenue was $44.6 million, compared with $47.7 million in the prior-year period, a decrease of approximately 7%.
●Gross profit was $36.4 million, compared with $40.7 million in the prior-year period. Gross margin was approximately 82%, compared with approximately 85% in the prior-year period, a decline of approximately 370 basis points, primarily reflecting the gross revenue presentation of branded medications fulfilled by our pharmacy.
●Selling and marketing expenses decreased 18% year-over-year, and 34% sequentially, to $18.5 million.
●General and administrative expenses increased 6% year-over-year to $14.7 million, reflecting added clinical capacity.
●GAAP net loss from continuing operations attributable to common stockholders was $5.2 million, or $0.11 per share, compared with a GAAP net loss from continuing operations attributable to common stockholders of $5.4 million, or $0.12 per share, in the prior-year period.
●Adjusted EBITDA was a loss of approximately $0.4 million, compared with adjusted EBITDA of approximately $2.8 million in the prior-year period.
●Cash totaled $21.9 million as of September 30, 2026, and the Company had no debt at quarter end.
●The number of active subscribers increased 13% year-over-year to approximately 350,000 at quarter end.

 

 

 

 

($ in 000s)  Three Months Ended September 30,   Y-o-Y 
Key Performance Metrics  2026   2025   % Growth 
             
Revenue  $44,625   $47,728    -7%
                
Gross Profit  $36,376   $40,666    -11%
                
Gross Margin %   82%   85%   -370b pts 
                
Adjusted EBITDA  $(413)  $2,787    -115%
                
Active Subscribers   349,744    310,818    13%

 

Financial Guidance

 

For the fourth quarter of 2026, the Company expects:

 

●Revenue in the range of $46 million to $49 million.
●Adjusted EBITDA in the range of negative $4 million to negative $2 million.

 

For the full year 2026, the Company expects (revised from previous guidance):

 

●Revenue in the range of $188 million to $191 million, compared with previous guidance of $205.5 million to $212.5 million.
●Adjusted EBITDA in the range of negative $12.6 million to negative $10.6 million, compared with previous guidance of negative $6.0 million to breakeven.

 

 

 

 

Conference Call

 

LifeMD’s management will host a conference call today at 4:30 p.m. Eastern time to discuss the Company’s financial results and outlook, and answer questions. Details for the call are as follows:

 

Toll-free dial-in number: (877) 270-2148
International dial-in number: +1 (412) 902-6510
Conference ID: LifeMD, Inc. Third Quarter 2026 Results

 

A live and archived webcast will be available in the Investors section of the Company’s website at ir.lifemd.com.

 

About LifeMD, Inc.

 

LifeMD® is a leading virtual care company making high-quality healthcare more accessible, convenient, and affordable. Through its vertically integrated platform, LifeMD connects patients with a 50-state affiliated medical group, laboratory services, a state-of-the-art in-house pharmacy, and a U.S.-based patient care center. Together, these capabilities support care across more than 200 conditions, including primary care, men’s and women’s health, weight management, and hormone therapy. For more information, please visit LifeMD.com.

 

Cautionary Note Regarding Forward Looking Statements

 

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: “believe,” “expect,” “anticipate,” “project,” “should,” “plan,” “will,” “may,” “intend,” “estimate,” “predict,” “continue,” and “potential,” or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.

 

Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.

 

Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.

 

Investor Contact

[email protected]

 

Media Contact

[email protected]

Tables to Follow

++++++

 

 

 

 

LIFEMD, INC.

CONSOLIDATED BALANCE SHEETS

(Unaudited)

 

   September 30, 2026   December 31, 2025 
ASSETS          
           
Current Assets          
Cash  $21,921,769   $36,786,318 
Receivables, net   13,249,849    2,485,882 
Product deposit   218,690    320,217 
Inventory, net   10,348,601    2,773,576 
Other current assets   3,522,349    2,646,077 
Total Current Assets   49,261,258    45,012,070 
           
Non-current Assets          
Equipment, net   1,905,154    2,444,717 
Right of use assets, net   4,622,463    5,267,857 
Capitalized software, net   10,329,573    10,604,946 
Intangible assets, net   166,583    262,334 
Total Non-current Assets   17,023,773    18,579,854 
           
Total Assets  $66,285,031   $63,591,924 
           
LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY          
           
Current Liabilities          
Accounts payable  $37,736,899   $14,149,154 
Accrued expenses   12,842,607    14,214,393 
Current operating lease liabilities   691,719    642,422 
Deferred revenue   10,433,507    10,573,442 
Total Current Liabilities   61,704,732    39,579,411 
           
Long-term Liabilities          
Non-current operating lease liabilities   5,159,954    5,681,374 
Total Liabilities   66,864,686    45,260,785 
           
Commitments and Contingencies          
Stockholders’ (Deficit) Equity          
Series A Preferred Stock, $0.0001 par value; 1,610,000 shares authorized, 1,400,000 shares issued and outstanding as of September 30, 2026 and December 31, 2025   140    140 
Common Stock, $0.01 par value; 100,000,000 shares authorized, 48,358,877 and 46,760,016 shares issued, 48,255,837 and 46,656,976 outstanding as of September 30, 2026 and December 31, 2025, respectively   483,589    467,600 
Additional paid-in capital   255,443,609    251,455,616 
Accumulated deficit   (256,343,292)   (233,428,516)
Treasury stock, 103,040 shares, at cost, as of September 30, 2026 and December 31, 2025   (163,701)   (163,701)
Total LifeMD, Inc. Stockholders’ (Deficit) Equity   (579,655)   18,331,139 
Total Liabilities and Stockholders’ (Deficit) Equity  $66,285,031   $63,591,924 

 

 

 

 

LIFEMD, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
   2026   2025   2026   2025 
Telehealth revenue, net  $44,625,086   $47,727,942   $142,048,848   $146,861,697 
Cost of telehealth revenue   8,249,469    7,061,651    19,605,877    21,627,901 
Gross profit   36,375,617    40,666,291    122,442,971    125,233,796 
                     
Expenses                    
Selling and marketing expenses   18,500,609    22,563,994    76,411,416    66,988,030 
General and administrative expenses   14,654,524    13,800,377    43,468,661    42,995,255 
Other operating expenses   3,453,051    2,800,013    9,673,184    8,072,564 
Customer service expenses   2,351,426    2,784,320    8,103,717    9,086,549 
Development costs   1,882,508    1,844,269    5,470,005    5,526,379 
Total expenses   40,842,118    43,792,973    143,126,983    132,668,777 
                     
Operating loss from continuing operations   (4,466,501)   (3,126,682)   (20,684,012)   (7,434,981)
                     
Interest (expense) income, net   (3,212)   (260,621)   98,924    (1,385,046)
Loss on debt extinguishment   -    (1,155,851)   -    (1,155,851)
Loss from continuing operations before income taxes   (4,469,713)   (4,543,154)   (20,585,088)   (9,975,878)
                     
Income tax provision   -    (31,823)   -    (31,823)
Net loss from continuing operations   (4,469,713)   (4,574,977)   (20,585,088)   (10,007,701)
                     
Net income from discontinued operations   -    935,013    -    4,821,519 
Net loss   (4,469,713)   (3,639,964)   (20,585,088)   (5,186,182)
                     
Net income attributable to noncontrolling interests of discontinued operations   -    249,462    -    1,286,382 
                     
Net loss attributable to LifeMD, Inc.   (4,469,713)   (3,889,426)   (20,585,088)   (6,472,564)
                     
Preferred stock dividends   (776,563)   (776,563)   (2,329,688)   (2,329,688)
                     
Net loss attributable to LifeMD, Inc. common stockholders   (5,246,276)  $(4,665,989)  $(22,914,776)  $(8,802,252)
                     
Basic (loss) earnings per share attributable to LifeMD, Inc. common stockholders                    
Continuing operations   (0.11)  $(0.12)  $(0.48)  $(0.28)
Discontinued operations   -    0.01    -    0.08 
Basic loss per share   (0.11)  $(0.10)  $(0.48)  $(0.20)
                     
Diluted (loss) earnings per share attributable to LifeMD, Inc. common stockholders                    
Continuing operations   (0.11)  $(0.12)  $(0.48)  $(0.28)
Discontinued operations   -    0.01    -    0.08 
Diluted loss per share   (0.11)  $(0.10)  $(0.48)  $(0.20)
                     
Weighted average number of common shares outstanding:                    
Basic   48,182,152    46,162,625    47,772,180    44,575,553 
Diluted   48,182,152    46,162,625    47,772,180    44,575,553 

 

 

 

 

LIFEMD, INC.

 CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

   Three Months Ended September 30,   Nine Months Ended
September 30,
 
   2026   2025   2026   2025 
                 
CASH FLOWS FROM OPERATING ACTIVITIES                    
Net loss  $(4,469,713)  $(3,639,964)  $(20,585,088)  $(5,186,182)
Less: Net income from discontinued operations   -    935,013    -    4,821,519 
Net loss from continuing operations   (4,469,713)   (4,574,977)   (20,585,088)   (10,007,701)
Adjustments to reconcile net loss from continuing operations to net cash (used in) provided by operating activities:                    
Amortization of debt discount   -    33,481    -    234,369 
Amortization of capitalized software   1,727,834    1,597,030    5,116,366    4,712,732 
Amortization of intangibles   31,917    31,917    95,751    62,084 
Loss on debt extinguishment   -    1,155,851    -    1,155,851 
Depreciation of fixed assets   301,049    253,031    883,294    583,915 
Noncash operating lease expense   217,495    217,495    645,394    743,207 
Stock compensation expense   1,684,445    3,198,036    3,923,462    7,841,178 
                     
Changes in Assets and Liabilities                    
Receivables   (9,507,862)   (10,338)   (10,763,967)   2,618,396 
  Product deposit   25,069    (119,518)   101,527    (329,755)
  Inventory   (7,392,457)   (181,027)   (7,575,025)   (635,024)
  Other current assets   (1,035,546)   (1,382,528)   (876,272)   (558,239)
  Operating lease liabilities   (165,451)   (23,535)   (472,123)   (171,841)
  Deferred revenue   (357,714)   (2,322,589)   (139,935)   (4,864,738)
  Accounts payable   19,579,987    (4,591,851)   23,587,745    3,896,078 
  Accrued expenses   (1,588,687)   4,529,660    (1,371,786)   (1,109,939)
Net cash (used in) provided by operating activities of continuing operations   (949,634)   (2,189,862)   (7,430,657)   4,170,573 
Net cash provided by operating activities of discontinued operations   -    2,042,726    -    7,390,125 
Net cash (used in) provided by operating activities   (949,634)   (147,136)   (7,430,657)   11,560,698 
                     
CASH FLOWS FROM INVESTING ACTIVITIES                    
Cash paid for capitalized software costs   (1,322,921)   (1,937,544)   (4,840,993)   (5,884,672)
Purchase of equipment   (170,728)   (785,748)   (343,731)   (1,679,963)
Net cash used in investing activities of continuing operations   (1,493,649)   (2,723,292)   (5,184,724)   (7,564,635)
Net cash used in investing activities of discontinued operations   -    (871,188)   -    (2,596,766)
Net cash used in investing activities   (1,493,649)   (3,594,480)   (5,184,724)   (10,161,401)
                     
CASH FLOWS FROM FINANCING ACTIVITIES                    
Repayment of debt instruments   -    (16,667,433)   -    (18,719,721)
Sale of common stock under ATM, net   -    8,721,717    -    8,721,717 
Preferred stock dividends   (776,563)   (776,563)   (2,329,688)   (2,329,688)
Cash proceeds from exercise of warrants   -    464,950         464,950 
Cash proceeds from exercise of options   -    5,950    80,520    5,950 
Net cash used in financing activities of continuing operations   (776,563)   (8,251,379)   (2,249,168)   (11,856,792)
Net cash used in financing activities of discontinued operations   -    (449,539)   -    (761,658)
Net cash used in financing activities   (776,563)   (8,700,918)   (2,249,168)   (12,618,450)
                     
Net decrease in cash   (3,219,846)   (12,442,534)   (14,864,549)   (11,219,153)
Cash at beginning of period   25,141,615    36,228,305    36,786,318    35,004,924 
Cash at end of period   21,921,769    23,785,771    21,921,769    23,785,771 
Less: Cash of discontinued operations at end of period   -    2,838,484    -    2,838,484 
Cash of continuing operations at end of period  $21,921,769   $20,947,287   $21,921,769   $20,947,287 
                     
Cash paid for interest and taxes                    
Cash paid during the period for interest  $-   $241,464   $-   $1,461,032 
Cash paid during the period for taxes  $-   $14,617   $361,230   $482,471 
                     
Non-cash investing and financing activities                    
Cashless exercise of options  $-   $253   $-   $1,315 
Cashless exercise of warrants  $3,204   $-   $3,204   $3,901 
Stock issued for debt conversion  $-   $-   $-   $1,000,000 
Stock issued for asset acquisition  $-   $-   $-   $303,000 

 

 

 

 

About the Use of Non-GAAP Financial Measures

 

To supplement our financial information presented in accordance with GAAP, we use adjusted EBITDA as a non-GAAP financial measure to clarify and enhance an understanding of past performance. We believe that the presentation of this financial measure enhances an investor’s understanding of our financial performance. We further believe that this financial measure is a useful financial metric to assess our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business. We use certain financial measures for business planning purposes and in measuring our performance relative to that of our competitors.

 

Adjusted EBITDA is defined as net loss attributable to LifeMD, Inc. common stockholders before interest, taxes, depreciation, amortization, extraordinary litigation costs, severance and restructuring costs, acquisition expenses, insurance acceptance readiness expenses, preferred stock dividends, stock-based compensation expense, net income from discontinued operations and net income attributable to noncontrolling interests of discontinued operations. We have provided below a reconciliation of adjusted EBITDA to net loss attributable to LifeMD, Inc. common stockholders, its most directly comparable GAAP financial measure.

 

We believe the above financial measure is commonly used by investors to evaluate our performance and that of our competitors. However, our use of the term adjusted EBITDA may vary from that of others in our industry. Adjusted EBITDA should not be considered as an alternative to net loss before taxes, net loss per share, operating loss or any other performance measures derived in accordance with GAAP as measures of performance.

 

Reconciliation of Net Loss Attributable to LifeMD, Inc. Common Stockholders to Adjusted EBITDA

(in whole numbers, unaudited)

 

   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
   2026   2025   2026   2025 
Net loss attributable to LifeMD, Inc. common stockholders  $(5,246,276)  $(4,665,989)  $(22,914,776)  $(8,802,252)
                     
Interest (income) expense, net   3,212    227,140    (98,924)   1,150,677 
Depreciation and amortization expense   2,060,800    1,881,978    6,095,411    5,358,731 
Amortization of debt discount   -    33,481    -    234,369 
Loss on debt extinguishment   -    1,155,851    -    1,155,851 
Financing transactions expense   -    97,699    -    97,699 
Litigation costs (a)   64,328    959,803    1,112,269    1,699,462 
Severance and restructuring costs   243,885    -    992,879    102,417 
Acquisitions expenses   -    (231,571)   -    1,783,206 
Insurance acceptance readiness   -    8,190    -    183,330 
Taxes   -    31,823    -    31,823 
Preferred stock dividends   776,563    776,563    2,329,688    2,329,688 
Stock compensation expense   1,684,445    3,198,036    3,923,462    7,841,178 
Net income from discontinued operations   -    (935,013)   -    (4,821,519)
Net income attributable to noncontrolling interests of discontinued operations   -    249,462    -    1,286,382 
                     
Adjusted EBITDA  $(413,043)  $2,787,452   $(8,559,991)  $9,631,041 

 

(a) For the three and nine months ended September 30, 2026 and 2025, the Company included costs related to: (1) a class action complaint  captioned Johnston v. LifeMD, Inc., et al., against the Company and certain executive officers alleging: (i) violations of Section 10(b) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder by all defendants for making false and misleading statements; and (ii) violations of Section 20(a) of the Securities Exchange Act of 1934, as amended, by the individual officer defendants for violating their duty to disseminate accurate and truthful information, and (2) a heavily negotiated executive separation agreement. For the three and nine months ended September 30, 2025, the Company also included costs related to a class action complaint alleging, inter alia, unauthorized disclosure of certain information of class members to third parties (the Marden v. LifeMD, Inc. case).